Pembrolizumab reduces recurrence risk in stage II melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-022-00638-w
Abstract: 0123456789();: suggests that pembrolizumab can eradicate micrometastatic disease, which might ultimately translate into an overall survival benefit. Pembrolizumab was associated with mostly low-grade adverse events, with grade 3–4 toxicities in only 16% of patients (compared… read more here.
Keywords: pembrolizumab; reduces recurrence; pembrolizumab reduces; stage melanoma ... See more keywords